Replies to post #116640 on Biotech Values

[DewDiligence]

I am confident that the FDA is using MNTA version of enoxaparin as the bar that needs to be met.

This is consistent with the political impetus from Congress to err on the side of caution in the wake of the Vioxx, Avandia, and contaminated-heparin incidents. Please see #msg-56450420 for related musings.